Kidney Cancer

Aims & Scope

Kidney Cancer is an international multidisciplinary journal to facilitate progress in understanding the epidemiology/etiology, genetics, molecular correlates, pathogenesis, pathobiology, and pharmacology of tumors of the kidney with the objective of improving diagnosis, treatment, and survivorship in patients.

The journal is directed primarily at researchers and clinicians working on these areas, with some content aimed at patients/patient advocates with these conditions.

With this objective in mind, the journal publishes original research reports, systematic and regular reviews, short communications, and letters-to-the-editor in basic science, translational research and clinical medicine.

The journal is committed to the highest ethical standards and best practices, and prospective authors are encouraged to consult the relevant author instructions and policies on the website at the time of submission as these are updated regularly to reflect changing guidelines.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,800.00 USD. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Diagnostic Imaging for Solid Renal Tumors: A Pictorial Review

  Citation: 86

  Authors: Tim J., Jurgen J., Peter F.A.

• The ‘Achilles Heel’ of Metabolism in Renal Cell Carcinoma: Glutaminase Inhibition as a Rational Treatment Strategy

  Citation: 56

  Authors: Christian R., Viola J., Alice C.

• A Review of Papillary Renal Cell Carcinoma and MET Inhibitors

  Citation: 53

  Authors: Katherine Emilie, Mehmet Asim

• Association of Circulating Tumor DNA (ctDNA) Detection in Metastatic Renal Cell Carcinoma (mRCC) with Tumor Burden

  Citation: 43

  Authors: Manuel Caitano, Paulo Gustavo, Nazli, JoAnn, Jeremy, Richard B., Kimberly C., Sumanta K.

• Molecular Classification of Renal Cell Carcinoma and Its Implication in Future Clinical Practice

  Citation: 41

  Authors: Jozefina, Yann-Alexandre, Wolf Herve, James J.

• Genomic Alterations and Outcomes with VEGF-Targeted Therapy in Patients with Clear Cell Renal Cell Carcinoma

  Citation: 37

  Authors: M.I., B., S., K.M., D.T., A., M., M., W., Y.B., C.H., D.R., A.A., R.J., J.J., M.H.

• Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107

  Citation: 34

  Authors: Przemyslaw W., Catherine M., Xiwei, Melissa R., Elizabeth R., Neeraj, Nicholas J., Jinhui, Shu, Ian M., Primo

• Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)

  Citation: 27

  Authors: Pooja, W. Kimryn

• “PROBE”ing the Role of Cytoreductive Nephrectomy in Advanced Renal Cancer

  Citation: 23

  Authors: Hannah, Brittney H., Simpa S., Hyung, Ulka

• Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)

  Citation: 16

  Authors: Timothy W., Melissa, Catherine M., Elisabeth I., Ganesh S., Philip C., Mark N., Maxwell V., Primo, Nicholas J., Ian Murchie, Christopher W.